Peptide Therapies for IBS: Approved and Emerging
Gut Peptides and IBS
33.6%
of IBS-C patients on linaclotide met the FDA composite responder endpoint in phase 3 trials, versus 21.0% on placebo.
Chey et al., Am J Gastroenterol, 2012
Chey et al., Am J Gastroenterol, 2012
View as imageIrritable bowel syndrome affects an estimated 10-15% of the global population, yet for decades the treatment options were limited to symptom management with fiber, antispasmodics, and loperamide. The approval of linaclotide in 2012, plecanatide in 2017, and tenapanor in 2022 changed the landscape for IBS with constipation (IBS-C) by introducing drugs that target specific molecular pathways in the gut lining. Two of these, linaclotide and plecanatide, are synthetic peptides that activate guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells. The third, tenapanor, is a small molecule that blocks sodium absorption. Beyond these approved options, research into gut peptide signaling, from ghrelin and motilin to GLP-1 and peptide YY, is opening new avenues for both IBS-C and IBS-D. For the underlying biology, see Gut Peptide Dysregulation in IBS: What Goes Wrong and the pillar article Plecanatide: The Uroguanylin Analog for IBS-C.
Key Takeaways
- Linaclotide (290 mcg) produced a 33.6% FDA composite responder rate versus 21.0% for placebo in a 26-week phase 3 trial, with pain relief starting at week 1 (Chey et al., 2012)
- Plecanatide (3 mg) achieved a 30.2% overall responder rate versus 17.8% placebo, with improvement in bloating, cramping, and abdominal discomfort by week 1 (Brenner et al., 2018)
- Tenapanor (50 mg twice daily) met its primary endpoint with 27.0% responders versus 18.7% on placebo, working through a distinct sodium-blocking mechanism (Chey et al., 2020)
- IBS patients show altered levels of serotonin, peptide YY, ghrelin, and motilin in colonic tissue, suggesting peptide-level dysfunction drives symptoms (El-Salhy et al., 2012)
- GLP-1 receptor agonists reduced IBS symptom severity by inhibiting gut motility in early clinical data, though large trials are lacking (O'Malley et al., 2019)
- Diarrhea is the primary adverse event across all three approved IBS-C drugs, causing discontinuation in 1.2-6.5% of patients
The Three Approved Drugs: How They Work
All three FDA-approved IBS-C secretagogues work at the intestinal epithelial surface, but through different molecular targets.
Linaclotide: The GC-C Agonist
Linaclotide is a 14-amino acid synthetic peptide structurally related to the endogenous peptides guanylin and uroguanylin. It binds to guanylate cyclase-C receptors on the luminal surface of intestinal epithelial cells, stimulating production of cyclic guanosine monophosphate (cGMP). This triggers two effects: chloride and bicarbonate secretion into the intestinal lumen (which draws water and accelerates transit) and reduction of visceral pain signaling through inhibition of pain-sensing nerve fibers.
The dual mechanism is what separates linaclotide from older laxatives. Standard osmotic laxatives increase fluid secretion but do nothing for abdominal pain. Linaclotide addresses both, with the pain reduction occurring through a cGMP-mediated pathway that dampens visceral afferent nerve firing. Busby et al. (2013) characterized its pharmacologic properties, confirming that linaclotide is minimally absorbed systemically and acts almost entirely within the gut lumen.[1] For a detailed breakdown of this drug's mechanism, see Linaclotide: How a Peptide Drug Treats IBS with Constipation.
Plecanatide: The Uroguanylin Analog
Plecanatide is a 16-amino acid synthetic peptide designed to mimic uroguanylin, the endogenous GC-C ligand that regulates intestinal fluid and electrolyte balance. Unlike linaclotide, which has higher potency at GC-C receptors, plecanatide was designed to replicate the pH-dependent binding profile of uroguanylin, activating preferentially in the proximal small intestine where pH is mildly acidic. This pH-sensitivity was intended to produce a more physiologically natural pattern of fluid secretion. For the full profile of this drug, see Plecanatide: The Uroguanylin Analog for IBS-C.
Tenapanor: The NHE3 Inhibitor
Tenapanor is not a peptide; it is a small molecule that inhibits sodium/hydrogen exchanger isoform 3 (NHE3) on the intestinal epithelial surface. By blocking sodium absorption, it increases water retention in the intestinal lumen and accelerates transit. Its inclusion in IBS-C treatment discussions is relevant because it fills a mechanistic gap that the peptide-based GC-C agonists do not cover, and it represents the alternative pharmacological approach when peptide drugs fail or are not tolerated.
What the Phase 3 Trial Numbers Show
Linaclotide Phase 3 Data
Two pivotal trials established linaclotide's efficacy for IBS-C. In the 26-week trial (Trial 31), 33.6% of linaclotide-treated patients (136/405) met the FDA composite responder endpoint versus 21.0% (83/395) on placebo. The composite required both a 30% or greater reduction in worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) per week from baseline, in the same week, for at least 6 of 12 weeks.
For individual endpoints, 54.8% of linaclotide patients were abdominal pain responders versus 41.8% on placebo in Trial 31. CSBM responder rates were 47.6% versus 22.6%. Pain improvement was measurable by week 1, with continued gains through weeks 6 to 9.
The 12-week trial (Trial 302) produced consistent results: an FDA composite responder rate of 12.1% for linaclotide versus 5.1% for placebo using a stricter weekly composite, and CSBM responder rates of 47.6% versus 22.6%.
Diarrhea was the dominant adverse event, causing discontinuation in 4.5% of linaclotide patients versus 0.2% on placebo.
Plecanatide Phase 3 Data
Two identical phase 3 trials randomized IBS-C patients (Rome III criteria) to placebo, plecanatide 3 mg, or plecanatide 6 mg for 12 weeks. In the integrated analysis, 25.6% of patients on plecanatide 3 mg and 26.7% on 6 mg met the overall response endpoint versus 16.0% on placebo (both doses P < 0.001 versus placebo).
Study 1 showed a 30.2% responder rate for the 3 mg dose versus 17.8% for placebo. Study 2 showed 21.5% for 3 mg versus 14.2% for placebo. Improvements in abdominal discomfort, fullness, bloating, and cramping were measurable by week 1 (week 2 for abdominal pain specifically).
Diarrhea occurred in 4.3% (3 mg) and 4.0% (6 mg) versus 1.0% on placebo. Discontinuation due to diarrhea was 1.2% and 1.4% respectively.
Tenapanor Phase 3 Data
The T3MPO-1 trial (12 weeks) showed 27.0% of tenapanor patients met the primary composite endpoint versus 18.7% on placebo (P = 0.020). 44% were abdominal pain responders versus 33% on placebo.
The T3MPO-2 trial (26 weeks) demonstrated sustained efficacy: 36.5% of tenapanor patients were 6-of-12 week combined responders versus 23.7% on placebo. Mean improvements in CSBM frequency and abdominal pain were maintained through the full 26-week period.
Diarrhea rates were higher with tenapanor: 16.0% versus 3.7% on placebo in T3MPO-2, with 6.5% of tenapanor patients discontinuing due to diarrhea.
How These Drugs Compare
| Drug | Type | Mechanism | FDA Approval | IBS-C Responder Rate | Pain Responder Rate | Diarrhea-Related Discontinuation |
|---|---|---|---|---|---|---|
| Linaclotide 290 mcg | 14-aa peptide | GC-C agonist | 2012 | 33.6% vs 21.0% | 54.8% vs 41.8% | 4.5% |
| Plecanatide 3 mg | 16-aa peptide | GC-C agonist (pH-dependent) | 2017 | 30.2% vs 17.8% | Improved vs placebo | 1.2% |
| Tenapanor 50 mg | Small molecule | NHE3 inhibitor | 2022 | 27.0% vs 18.7% | 44% vs 33% | 6.5% |
Linaclotide shows the highest absolute responder rates. Plecanatide has the lowest diarrhea-related discontinuation rate. Tenapanor offers a mechanistically distinct option for patients who do not respond to GC-C agonists. Recent data from Digestive Disease Week 2025 suggest that switching between GC-C agonists (linaclotide to plecanatide or vice versa) produces moderate improvement in patients who fail the first agent, with a median response score of 2.0 (moderate improvement) on a standardized scale.
The Peptide Biology Behind IBS Symptoms
The approved drugs target the secretory dysfunction in IBS-C, but the broader peptide landscape in IBS involves disrupted signaling across multiple hormone systems.
El-Salhy et al. (2012) found that patients with IBS had significantly lower densities of serotonin-producing enterochromaffin cells and peptide YY (PYY)-producing L cells in the colon compared to healthy controls.[2] El-Salhy (2020) further characterized PYY's role, noting that this peptide normally slows colonic transit and promotes water absorption; its deficiency in IBS patients may contribute to the disordered motility patterns seen in both IBS-C and IBS-D subtypes.[3]
Zhang et al. (2008) documented broader correlations between gut hormone levels and IBS severity, finding altered patterns of motilin, vasoactive intestinal peptide, and somatostatin in IBS patients.[4] Motilin, the peptide that drives the migrating motor complex (the "cleaning wave" that moves through the gut between meals), and ghrelin are both prokinetic targets under investigation for motility disorders.[5] For the role of ghrelin in gut motility, see Ghrelin and Gut Motility: The Hunger Hormone's Digestive Role.
Zhang et al. (2025) provided evidence that milk-derived bioactive peptides can alleviate IBS symptoms by suppressing colonic mast cell activation, a mechanism distinct from the secretagogue approach of linaclotide and plecanatide.[6] This suggests the next generation of peptide-based IBS therapies may target the inflammatory and immune components rather than just secretory function.
What Is in the Pipeline
GLP-1 Receptor Agonists for IBS
O'Malley et al. (2019) reviewed the evidence for GLP-1 in IBS pathophysiology, noting that GLP-1 receptors are expressed throughout the gut and central nervous system, and that GLP-1 slows gastric emptying, inhibits the migrating motor complex, and modulates visceral sensation.[7] The GLP-1 analog ROSE-010 was tested in a placebo-controlled crossover trial in IBS patients and decreased gastrointestinal motility while relieving acute discomfort. A 2025 systematic review and meta-analysis in Frontiers in Endocrinology found that GLP-1 receptor agonists improved IBS symptom severity scores, though the authors noted that most evidence comes from patients taking GLP-1 drugs for diabetes or obesity who happened to have co-existing IBS, not from IBS-specific trials.
IBS-C patients were found to have lower mucosal expression of GLP-1 receptors and lower serum GLP-1 concentrations, suggesting a possible deficiency state. Whether GLP-1 agonists like semaglutide or tirzepatide will eventually receive IBS indications depends on dedicated randomized controlled trials, which have not yet been completed. The main concern is the paradox: GLP-1 agonists slow gut transit, which could worsen constipation-predominant IBS while potentially helping diarrhea-predominant IBS. For more on GLP-1 drug effects, see GLP-1 Side Effects: What to Expect and What's Actually Dangerous.
Opioid Peptide Receptors and IBS-D
Corazziari (1999) reviewed the role of opioid ligands in IBS, establishing that mu-opioid receptors in the gut regulate motility, secretion, and visceral sensation.[8] This basic science eventually led to eluxadoline (Viberzi), a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist approved in 2015 for IBS-D. In two phase 3 trials (N = 2,427), 22.7% of eluxadoline patients met a composite improvement endpoint for pain and diarrhea versus 10.3% on placebo. The dual receptor activity allows it to slow motility and reduce visceral hypersensitivity without the full constipating effects of pure mu-opioid agonists like loperamide.
Motilin and Ghrelin Agonists
Chen et al. (2012) characterized the overlapping roles of ghrelin and motilin in gastrointestinal motility.[9] Both peptides are prokinetic: they stimulate gastric emptying and intestinal contractions. Motilin receptors are the target of erythromycin's prokinetic effects (a known off-label use for gastroparesis). Dedicated motilin agonists and ghrelin agonists are in preclinical and early clinical development for motility disorders including IBS-C, though none have reached phase 3.
De Smet et al. (2009) reviewed motilin and ghrelin as prokinetic drug targets, noting that camicinal (a motilin receptor agonist) showed promise in phase 2 for accelerating gastric emptying but was not advanced for IBS specifically.[5] The challenge with motilin agonists is tachyphylaxis: the receptor desensitizes with repeated dosing, limiting long-term efficacy.
Anti-Inflammatory Peptides
The mast cell-peptide connection is an emerging area. Wang et al. (2024) showed that certain drugs modulate GDF15 and GLP-1 expression via motilin receptors in the intestine.[10] Zhang et al. (2025) demonstrated that milk-derived peptides suppressed mast cell activation and improved IBS symptoms in animal models.[6] Mast cell activation, with release of histamine, tryptase, and prostaglandins, drives visceral hypersensitivity in a subset of IBS patients. Peptide-based approaches that modulate this immune activation represent a conceptually different treatment strategy from the current secretagogue drugs.
What the Current Drugs Cannot Do
All three approved IBS-C drugs share a fundamental limitation: they address secretory dysfunction and, to varying degrees, visceral pain, but they do not treat the underlying cause of IBS. Their efficacy is moderate. Even in the best trial results, two-thirds of patients do not meet the composite responder endpoint. Diarrhea, the most common side effect, reflects the drugs' mechanism (increased intestinal fluid secretion) taken too far.
For IBS-D, the options are even more limited. Eluxadoline works through opioid receptors, not peptide hormone pathways, and carries a boxed warning for pancreatitis in patients without a gallbladder.
The gap between approved therapies and the complexity of IBS pathophysiology is wide. Multiple peptide systems, including serotonin, PYY, motilin, ghrelin, GLP-1, CCK, and somatostatin, are simultaneously dysregulated in IBS patients. Current drugs target a single pathway. Future peptide-based IBS therapies will likely need to address the gut-brain axis connections, the mast cell-nerve interactions, and the peptide hormone imbalances simultaneously to improve on the 25-34% responder rates seen with existing treatments.
The Bottom Line
Three drugs targeting intestinal secretion are now FDA-approved for IBS-C: two synthetic peptides (linaclotide and plecanatide) that activate GC-C receptors, and one small molecule (tenapanor) that blocks sodium absorption. Responder rates range from 25-34% versus 14-21% on placebo. The pipeline includes GLP-1 receptor agonists for IBS-D, motilin and ghrelin agonists for motility disorders, and anti-inflammatory peptides targeting mast cell activation. Current drugs address one pathway in a multi-system disorder, leaving substantial room for improvement.